|
Teva's DuoResp Spiromax receives EC marketing authorization for treatment of …
News-Medical.net Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) announced today that the European Commission has granted marketing authorization for DuoResp Spiromax® for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) … Teva Gets Approval To Market DuoResp Spiromax In Europe |
View full post on asthma – Google News